Combining a breast cancer patient's clinical characteristics with a genomic profile of her tumor may provide important information for predicting an individual patient's prognosis and accurately guiding treatment options.

CHICAGO -- A protein that governs development of human embryonic stem cells (hESCs) also inhibits the growth and spread of malignant melanoma, the deadliest skin cancer, Northwestern University researchers have discovered. Metastatic melanoma, which develops from the transformation of skin

Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher.

The question of lingering effects from hormone therapy is especially relevant because so many women went off the drugs in 2002. That was the year researchers with the Women's Health Initiative dropped a bombshell: The huge research project, which was

A new study provides valuable insight into a previously undescribed mechanism that regulates a prominent cancer-associated protein. The research, published by Cell Press in the February 29th issue of Molecular Cell, will enhance understanding of the fundamental processes that contribute

Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model

Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. A study published in the open access journal Breast Cancer Research shows that patients with tumours that are negative for estrogen receptor

A new study from the American Cancer Society finds that while breast cancer death rates are decreasing for white women in every U.S. state, for African American women, death rates are either flat or rising in at least half the

SEATTLE -- Cell Therapeutics, Inc. (CTI) today announced that patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) treated with fludarabine and mitoxantrone, followed by administration of Zevalin(R) (Ibritumomab Tiuxetan), achieved 96 percent complete remission (CR), an estimated three-year progression-free survival